Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation

Mayako Uchida, Hiroaki Ikesue, Toshihiro Miyamoto, Koji Kato, Kimitaka Suetsugu, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Katsuto Takenaka, Tsuyoshi Muta, Hiromi Iwasaki, Takanori Teshima, Motoaki Shiratsuchi, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5- HT3 antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60-90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1-2 nausea, in the aprepitant group was significantly higher than that in the control group (42% vs. 5%, p=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.

Original languageEnglish
Pages (from-to)819-824
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume36
Issue number5
DOIs
Publication statusPublished - May 1 2013

Fingerprint

aprepitant
Antiemetics
Hematopoietic Stem Cell Transplantation
Safety
Drug Therapy
Granisetron
Peripheral Blood Stem Cell Transplantation
Drug-Related Side Effects and Adverse Reactions
Vomiting
Neurokinin-1 Receptor Antagonists
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Control Groups
Hematologic Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. / Uchida, Mayako; Ikesue, Hiroaki; Miyamoto, Toshihiro; Kato, Koji; Suetsugu, Kimitaka; Ichinose, Kimiko; Hiraiwa, Hiromi; Sakurai, Asako; Takenaka, Katsuto; Muta, Tsuyoshi; Iwasaki, Hiromi; Teshima, Takanori; Shiratsuchi, Motoaki; Egashira, Nobuaki; Akashi, Koichi; Oishi, Ryozo.

In: Biological and Pharmaceutical Bulletin, Vol. 36, No. 5, 01.05.2013, p. 819-824.

Research output: Contribution to journalArticle

Uchida, Mayako ; Ikesue, Hiroaki ; Miyamoto, Toshihiro ; Kato, Koji ; Suetsugu, Kimitaka ; Ichinose, Kimiko ; Hiraiwa, Hiromi ; Sakurai, Asako ; Takenaka, Katsuto ; Muta, Tsuyoshi ; Iwasaki, Hiromi ; Teshima, Takanori ; Shiratsuchi, Motoaki ; Egashira, Nobuaki ; Akashi, Koichi ; Oishi, Ryozo. / Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. In: Biological and Pharmaceutical Bulletin. 2013 ; Vol. 36, No. 5. pp. 819-824.
@article{64ff6ae5acb64c49bdaba56d3ef39236,
title = "Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation",
abstract = "For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5- HT3 antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60-90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1-2 nausea, in the aprepitant group was significantly higher than that in the control group (42{\%} vs. 5{\%}, p=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.",
author = "Mayako Uchida and Hiroaki Ikesue and Toshihiro Miyamoto and Koji Kato and Kimitaka Suetsugu and Kimiko Ichinose and Hiromi Hiraiwa and Asako Sakurai and Katsuto Takenaka and Tsuyoshi Muta and Hiromi Iwasaki and Takanori Teshima and Motoaki Shiratsuchi and Nobuaki Egashira and Koichi Akashi and Ryozo Oishi",
year = "2013",
month = "5",
day = "1",
doi = "10.1248/bpb.b12-01012",
language = "English",
volume = "36",
pages = "819--824",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - Effectiveness and safety of antiemetic aprepitant in japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation

AU - Uchida, Mayako

AU - Ikesue, Hiroaki

AU - Miyamoto, Toshihiro

AU - Kato, Koji

AU - Suetsugu, Kimitaka

AU - Ichinose, Kimiko

AU - Hiraiwa, Hiromi

AU - Sakurai, Asako

AU - Takenaka, Katsuto

AU - Muta, Tsuyoshi

AU - Iwasaki, Hiromi

AU - Teshima, Takanori

AU - Shiratsuchi, Motoaki

AU - Egashira, Nobuaki

AU - Akashi, Koichi

AU - Oishi, Ryozo

PY - 2013/5/1

Y1 - 2013/5/1

N2 - For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5- HT3 antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60-90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1-2 nausea, in the aprepitant group was significantly higher than that in the control group (42% vs. 5%, p=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.

AB - For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5- HT3 antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60-90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1-2 nausea, in the aprepitant group was significantly higher than that in the control group (42% vs. 5%, p=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.

UR - http://www.scopus.com/inward/record.url?scp=84876926679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876926679&partnerID=8YFLogxK

U2 - 10.1248/bpb.b12-01012

DO - 10.1248/bpb.b12-01012

M3 - Article

C2 - 23649338

AN - SCOPUS:84876926679

VL - 36

SP - 819

EP - 824

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -